KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Asset Writedowns and Impairment (2016 - 2019)

Historic Asset Writedowns and Impairment for Arbutus Biopharma (ABUS) over the last 5 years, with Q3 2019 value amounting to $43.8 million.

  • Arbutus Biopharma's Asset Writedowns and Impairment rose 19596.92% to $43.8 million in Q3 2019 from the same period last year, while for Dec 2020 it was $43.8 million, marking a year-over-year decrease of 2525.45%. This contributed to the annual value of $43.8 million for FY2019, which is 19596.92% up from last year.
  • Arbutus Biopharma's Asset Writedowns and Impairment amounted to $43.8 million in Q3 2019, which was up 19596.92% from $14.8 million recorded in Q3 2018.
  • In the past 5 years, Arbutus Biopharma's Asset Writedowns and Impairment ranged from a high of $156.3 million in Q2 2016 and a low of $1.0 million during Q4 2015
  • Over the past 5 years, Arbutus Biopharma's median Asset Writedowns and Impairment value was $40.8 million (recorded in 2017), while the average stood at $55.9 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Asset Writedowns and Impairment surged by 942536.87% in 2016, and later plummeted by 5788.51% in 2017.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Asset Writedowns and Impairment stood at $1.0 million in 2015, then skyrocketed by 9425.37% to $96.9 million in 2016, then plummeted by 57.89% to $40.8 million in 2017, then plummeted by 63.7% to $14.8 million in 2018, then skyrocketed by 195.97% to $43.8 million in 2019.
  • Its Asset Writedowns and Impairment was $43.8 million in Q3 2019, compared to $14.8 million in Q3 2018 and $40.8 million in Q4 2017.